JZMed

Proteomics research continues to be a booming business in China, with the market over the last few years having grown at around 30 percent to 35 percent annually, according to estimates from biotech consulting firm JZMed.

BGI, which, according to an official, generated roughly $6.2 million in proteomics revenue last year, plans to buy around 15 new high-resolution machines and 30 to 40 triple quadrupoles as part of its efforts to expand into the clinical proteomics and pharma markets.